A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (NCT05451810)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Life expectancy \>3 months on standard of care (SOC) treatment.
2. Meets the following disease activity criteria: \-- Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL):
3. Documented CD20+ mature B-cell neoplasm according to the the 5th edition of World Health Organization (WHO) classification of Haematolymphoid Tumours, based on most recent representative pathology report;
4. Diffuse large B-cell lymphoma, not otherwise specified (NOS) (de novo or transformed from follicular lymphoma (FL) or Marginal Zone Lymphoma \[MZL\]);
5. High-grade B-cell Lymphoma including "double-hit" or "triple-hit" DLBCL (technically classified in WHO 2022 or 2016 as high-grade B-cell lymphoma \[HGBCL\], with MYC and BCL2 and/or BCL6 translocations).
6. Follicular large B-cell lymphoma (FLBL, formerly FL grade 3B);
7. Relapsed or refractory disease and previously treated with at least 1 prior systemic antineoplastic therapies including at least 1 anti-CD20 monoclonal antibody-containing therapy; Note: Relapsed disease is defined as disease that previously responded to therapy but progressed \>= 6 months after completion of therapy. Refractory disease is defined as disease that either progressed during therapy, failed to achieve an objective response to prior therapy, or progressed within 6 months after completion of therapy (including maintenance therapy).
8. Either failed prior autologous hematopoietic stem cell transplantation (HSCT), or ineligible for autologous HSCT including but not limited to age, Eastern Cooperative Oncology Group (ECOG) performance status, participant decision, comorbidities and/or insufficient response to prior treatment.
9. R/R Follicular Lymphoma:
10. Documented CD20+ mature B-cell neoplasm according to the 5th edition of WHO classification of Haematolymphoid Tumours, based on representative pathology report; \--- Classic FL (cFL) (previously FL grade 1, 2, or 3a) without clinical or pathological evidence of transformation;
11. Relapsed or refractory disease and previously treated with at least 2 prior lines of systemic antineoplastic therapies including at least 1 anti-CD20 monoclonal antibody containing therapy; Note: Relapsed disease is defined as disease that previously responded to therapy but progressed \>= 6 months after completion of therapy. Refractory disease is defined as disease that either progressed during therapy, failed to achieve an objective response to prior therapy, or progressed within 6 months after completion of therapy (including maintenance therapy).
12. Previously treated with an alkylating agent or lenalidomide;

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (72 Sites)

• Infirmary Health - Infirmary Cancer Care at Mobile Infirmary /ID# 264630 — Mobile, Alabama
• University of Arkansas for Medical Sciences /ID# 244562 — Little Rock, Arkansas
• Highlands Oncology Group, PA /ID# 245002 — Springdale, Arkansas
• Beverly Hills Cancer Center /ID# 255327 — Beverly Hills, California
• Compassionate Cancer Care Research Group - Fountain Valley /ID# 246133 — Fountain Valley, California
• UCSF Fresno /ID# 263286 — Fresno, California
• University of California, Los Angeles /ID# 244573 — Los Angeles, California
• Rocky Mountain Cancer Centers - Boulder /ID# 247653 — Boulder, Colorado
• Bennett Cancer Center - Stamford Hospital /ID# 244530 — Stamford, Connecticut
• MedStar Washington Hospital Center /ID# 246068 — Washington D.C., District of Columbia
• Cancer Specialists of North Florida /ID# 261842 — Jacksonville, Florida
• Florida Cancer Specialists /ID# 260854 — Lake Mary, Florida
• Mount Sinai Medical Center-Miami Beach /ID# 249045 — Miami Beach, Florida
• Memorial Hospital West /ID# 248432 — Pembroke Pines, Florida
• BRCR Medical Center Inc /ID# 262527 — Tamarac, Florida
• Cleveland Clinic Florida /ID# 244532 — Weston, Florida
• Emory University, Winship Cancer Institute /ID# 246056 — Atlanta, Georgia
• University of Illinois at Chicago /ID# 245038 — Chicago, Illinois
• Illinois Cancer Specialists /ID# 247655 — Niles, Illinois
• Parkview Comprehensive Cancer Center /ID# 244545 — Fort Wayne, Indiana
• Indiana Blood & Marrow Transpl /ID# 244971 — Indianapolis, Indiana
• University of Iowa Health Care /ID# 258227 — Des Moines, Iowa
• Our Lady Of The Lake Regional Medical Center /ID# 255008 — Baton Rouge, Louisiana
• American Oncology Partners of Maryland /ID# 244968 — Bethesda, Maryland
• Maryland Oncology Hematology /ID# 254192 — Columbia, Maryland

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.